|Bid||79.75 x 1100|
|Ask||80.00 x 1000|
|Day's Range||79.87 - 81.10|
|52 Week Range||75.62 - 103.16|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||22.80|
|Earnings Date||Jul 25, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||4.28 (5.39%)|
|1y Target Est||89.73|
Many who want to get marijuana legally turn to Weedmaps ($WEEDMAPS), a user-generated-content website "where businesses and consumers can search and discover cannabis products" among other services it offers. In layman's terms, it is the Google Maps of weed. It's the legitimate, web version of asking a friend who knows a guy who knows a guy's cousin who might sell marijuana. For the sake of breaking down the weed industry in our own backyard, let's take a deeper dive into how many places one could get marijuana by doing a quick search on this website.
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA), Ontario is the first province to reimburse VENCLEXTA. VENCLEXTA is the first and only BCL-2 inhibitor to be approved in Canada . MONTREAL , May 23, 2019 /CNW/ - AbbVie (ABBV), a global, research and development-driven biopharmaceutical company, announced today that Ontario is the first province to reimburse VENCLEXTA® (venetoclax) monotherapy under its Drugs and Devices Division's (DDD) Exceptional Access Program effective May 13, 2019 .ii VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have no other treatment options.
FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes
When most people think of marijuana stocks, the last thing they think of is dividends. The legal marijuana industry is still very young, and new companies in growing industries need money to expand. Furthermore, U.S. investors in the marijuana space tend to currently focus on a handful of Canadian companies which have enjoyed the opportunity to list on U.S. exchanges.
MONTREAL , May 21, 2019 /CNW/ - AbbVie (ABBV), a global, research and development-driven biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced that ORILISSA™ (elagolix) 200 mg twice daily is now available.
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
An independent data monitoring committee recommended the study be stopped due to "lack of survival benefit" for patients receiving the treatment Depatux-M when compared with a placebo, AbbVie said. Depatux-M, when added to the standard regimen of radiation and temozolomide, failed to meet the main goal of achieving overall survival in newly diagnosed patients when compared to patients given a placebo along with radiation and temozolomide. The trial has been testing the drug to treat an aggressive form of brain cancer known as glioblastoma.
Shares of AbbVie Inc. fell 1.8% in premarket trade after the company announced that interim data from a Phase 3 trial of glioblastoma drug Depatux-M did not show any survival benefit to patients. An independent monitoring committee recommended stopping the trial, which was conducted in collaboration with the RTOG Foundation, a not-for-profit cancer research organization. "Glioblastoma patients and their caregivers face a devastating disease for which there are few therapeutic options. While we are disappointed that Depatux-M did not demonstrate a survival benefit in the INTELLANCE-1 study, we remain committed to discovering and developing therapies to address some of the most debilitating cancers," said Michael Severino, vice chairman and president of AbbVie, in a statement. AbbVie has halted enrollment in all of its Depatux-M studies. Shares of the company have fallen 14% in the year to date through Thursday, while the S&P 500 has gained 14.7%.
NORTH CHICAGO, Ill., May 17, 2019 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma (GBM), whose tumors have EGFR (epidermal growth factor receptor) amplification, demonstrated no survival benefit for patients receiving Depatux-M at an interim analysis. An Independent Data Monitoring Committee (IDMC) recommended the study be stopped due to lack of survival benefit for patients receiving Depatux-M compared with placebo when added to the standard regimen of radiation and temozolomide.
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
- FDA reviewed the submission under the Real-Time Oncology Review pilot program - Approval based on data from the Phase 3 CLL14 trial of VENCLEXTA® (venetoclax) in combination with obinutuzumab® - a randomized ...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.